Source-grounded facts extracted from Lyra Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lyra Therapeutics, Inc. terminated 880 Winter Street Sublease with RVAC Medicines (US), Inc. valued at termination payment of $2,100,000.00 (effective 2026-04-13).
“On April 13, 2026, Lyra Therapeutics, Inc. (the “Company”) entered into a Termination of Sublease with RVAC Medicines (US), Inc. to terminate the Company’s sublease for approximately 23,704 rentable square feet at 880 Winter Street, Waltham, Massachusetts.”
Lyra Therapeutics, Inc. terminated 880 Winter Street Lease with BXP Waltham Woods LLC valued at Forfeiture of $1,089,389.00 letter of credit security deposit and payment of $1,500,000.00 terminati (effective 2026-04-07).
“On April 7, 2026, the Company entered into a Lease Termination Agreement with BXP Waltham Woods LLC to terminate the Company’s lease for approximately 28,858 rentable square feet at 880 Winter Street, Waltham, Massachusetts.”
Lyra Therapeutics, Inc. terminated 480 Arsenal Street Lease with ARE-480 Arsenal Street, LLC valued at Forfeiture of $302,514.84 letter of credit security deposit and payment of $1,000,000.00 lease modif (effective 2026-03-31).
“On March 31, 2026, Lyra Therapeutics, Inc. (the “Company”) entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises with ARE-480 Arsenal Street, LLC to terminate the Company’s lease for approximately 22,343 rentable square feet at 480 Arsenal Way, Suites 200 and 200A, Watertown, Massachusetts.”
Lyra Therapeutics, Inc. reported a default on lease obligation with RVAC Medicines (US), Inc..
“On February 23, 2026, Lyra Therapeutics, Inc. (the “Company”) received a notice of default from RVAC Medicines (US), Inc. (“RVAC”) under the sublease agreement dated December 21, 2023 (the “Sublease”) between RVAC, as sublessor, and the Company, as sublessee, for office space located at 880 Winter Street, Suite 1002, Waltham, MA 02451 (the “Premises”).”
Lyra Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5550(b)).
“In the Staff Determination Letter, Nasdaq stated that, pursuant to Listing Rule 5101, it believes the Company is a “public shell” and that the continued listing of its securities is no longer warranted.”
Lyra Therapeutics, Inc. announced a restructuring affecting LYR-210 product candidate (substantially all of the Company’s remaining employees).
“On January 9, 2026, the Board of Directors of Lyra Therapeutics, Inc. (the “Company”) approved a plan to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis, and to implement a cost reduction plan that includes a workforce reduction impacting substantially all of the Company’s remaining employees, effective January 12, 2026, and other cost-saving actions to preserve capital (the “Plan”).”
Lyra Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“August 20, 2025, Lyra Therapeutics, Inc. (the “Company”) received a letter (the “Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of June 30, 2025 was approxim”
Lyra Therapeutics, Inc.: Certificate of Amendment to Restated Certificate of Incorporation to effect a 1-for-50 reverse stock split, effective May 27, 2025 at 5:00 p.m. Eastern Time (effective 2025-05-27).
“On May 27, 2025, Lyra Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended (the “Charter Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), effective May 27, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”)”
Lyra Therapeutics, Inc. announced a restructuring with charges of approximately $3.9 to $4.1 million (up to 87 employees).
“The Company currently estimates that it will incur charges of approximately $3.9 to $4.1 million in connection with the Workforce Reduction, primarily consisting of severance payments, employee benefits and related costs.”
Lyra Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter 2024 was $22.5 million compared to $16.3 million for the same period in 2023..
“Net loss for the first quarter 2024 was $22.5 million compared to $16.3 million for the same period in 2023.”
Edward T. Anderson resigned as Director at Lyra Therapeutics, Inc..
“On April 15, 2024, Edward T. Anderson resigned from the Board of Directors (the “ Board ”) of Lyra Therapeutics, Inc. (the “ Company ”) as well as the Audit Committee and Compensation Committee of the Board.”
Lyra Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“announced its financial results for the year ended December 31, 2023.”
Lyra Therapeutics, Inc. entered into Sublease with RVAC Medicines (US), Inc. valued at $1,801,503.96 (effective 2023-12-21).
“On December 21, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a sublease agreement (the “Sublease”) with RVAC Medicines (US), Inc., a Delaware corporation (the “Sublessor”), for approximately 23,704 square feet of laboratory and office space at 880 Winter Street in Waltham, Massachusetts (the “Premises”).”
Lyra Therapeutics, Inc.: Amended and restated bylaws to address universal proxy rules, streamline stockholder nomination and proposal procedures, require a non-white proxy card for soliciting stockholders, and delete obsolete provisions with technical changes (effective 2023-12-14).
“On December 14, 2023, the Board of Directors (the “ Board ”) of Lyra Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.”
Lyra Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
“Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.”
Lyra Therapeutics, Inc. entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. valued at $50.0 million (effective 2023-09-01).
“On September 1, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), for aggregate gross proceeds of up to $50.0 million (the “Shares”).”
Lyra Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $15.6 million.
“Net loss for the quarter ended June 30, 2023 was $15.6 million compared to $14.4 million for the same period in 2022.”
Lyra Therapeutics, Inc. amended Seventh Amendment to Lease with ARE-480 Arsenal Street, LLC valued at $95.67 per rentable square foot of the Premises per year (effective 2023-07-12).
“On July 12, 2023, Lyra Therapeutics, Inc. (the “ Company ”) entered into the Seventh Amendment to Lease (the “ Seventh Amendment ”) with ARE-480 Arsenal Street, LLC, a Delaware limited liability company (the “ Landlord ”), which amends the Lease Agreement, dated August 14, 2007, by and between the Company and the Landlord (as amended, the “ Lease ”), pursuant to which the Company leases approximately 22,343 rentable square feet of office space located in Suites 200 and 200A of 480 Arsenal Street, Watertown, Massachusetts (the “ Premises ”).”
Lyra Therapeutics, Inc. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-13 meeting.
“Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 9,471,462 8,427 20,492 0”
Lyra Therapeutics, Inc. shareholders approved Election of three Class III Directors to serve until the Company’s 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. at the 2023-06-13 meeting.
“NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Maria Palasis, Ph.D. 16,444,471 29,445 2,826,465 W. Bradford Smith 16,337,920 335,996 2,826,465 James R. Tobin 16,638.595 35,321 2,826,465”
Lyra Therapeutics, Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at aggregate gross proceeds of approximately $50.0 million (effective 2023-05-25).
“On May 25, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to sell securities to the Investors in a private placement (the “Private Placement”).”
Lyra Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $16.3 million.
“Net loss for the first quarter 2023 was $16.3 million compared to $11.9 million for the same period in 2022.”
Lyra Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss for the fourth quarter and full year ended December 31, 2022 was $14.2 million and $55.3 million, respectively.
“Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2022.”
Lyra Therapeutics, Inc. amended Sixth Amendment to Lease with ARE-480 Arsenal Street, LLC (effective 2022-11-14).
“On November 14, 2022, Lyra Therapeutics, Inc. (the “ Company ”) entered into the Sixth Amendment to Lease (the “ Sixth Amendment ”) with ARE-480 Arsenal Street, LLC, a Delaware limited liability company (the “ Landlord ”), which amends the Lease Agreement, dated August 14, 2007, by and between the Company and the Landlord (as amended, the “ Lease ”), pursuant to which the Company leases approximately 22,343 rentable square feet of office space located in Suites 200 and 200A of 480 Arsenal Street, Watertown, Massachusetts (the “ Premises ”).”
Lyra Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss for the quarter ended September 30, 2022 was $14.8 million.
“On November 8, 2022, Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.”
Harlan Waksal was appointed as Executive Chair at Lyra Therapeutics, Inc..
“On February 16, 2022, the Board of Directors of Lyra Therapeutics, Inc. (the “Company”) appointed Harlan Waksal, M.D. as a Class II director of the Company and Chairperson of the Board, and as the Executive Chair and an executive officer of the Company.”
R. Don Elsey departed as Chief Financial Officer at Lyra Therapeutics, Inc..
“Mr. Cavalier was also designated as the Company’s principal financial officer and principal accounting officer, and succeeds R. Don Elsey as Chief Financial Officer and principal financial officer and principal accounting officer.”
Jason Cavalier was appointed as Chief Financial Officer, Treasurer and Secretary at Lyra Therapeutics, Inc..
“On September 12, 2021, the Board of Directors (the “Board”) of Lyra Therapeutics, Inc. (the “Company”) appointed Jason Cavalier as Chief Financial Officer, Treasurer and Secretary of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.